C4X Discovery Ltd - LinkedIn

Skip to main content

C4X Discovery Ltd

Pharmaceutical Manufacturing

Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines

Follow

• View all 44 employees

• Report this company

About us

C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

Website http://www.c4xdiscovery.com/

External link for C4X Discovery Ltd

Industry Pharmaceutical Manufacturing Company size 11-50 employees Headquarters Manchester Type Privately Held Founded 2008 Specialties Drug Discovery, NMR, and Data Science

Locations

• Primary

  Manchester One

  53 Portland Street

  Manchester, M1 3LD, GB

  Get directions

• London, London NW1 1AD, GB

  Get directions

Employees at C4X Discovery Ltd

• Ana Manso Jones

  Associate Director | Portfolio Management | Alliance Management | Project Management | Project Selection | Strategic Partnerships

• Augustyniak Wojtek

  Senior Structural Analyst at C4X Discovery

• Nick Ray

  Chief Scientific Officer. C4X Discovery Ltd

• Mo Davis-Afsar

  Senior Software Developer at C4X Discovery

See all employees

Updates

• C4X Discovery Ltd

  4,907 followers

  3d
  • Report this post

  We are pleased to announce the appointment of DAVID LAWRENCE as Interim Non-Executive Chairman of C4X Discovery. Clive Dix.HonFBPhS steps down after an outstanding decade of leadership who, during his tenure, has driven the evolution of C4XD into a leading immuno-inflammatory therapeutics company. David brings extensive expertise, having overseen multiple fundraisings and transactions across global markets. Under David’s leadership, C4XD will continue to build on its strong foundation, progressing its pipeline and delivering on its strategic objectives. We thank Clive for his vision and dedication, which have been instrumental in positioning C4XD at the forefront of drug discovery. https://lnkd.in/dqutjwKC  #C4XDiscovery #Drugdiscovery #precisionmedicine”

  77 7 Comments Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  1mo
  • Report this post

  We're #hiring a new Senior Biostatistician in London Area, United Kingdom. Apply today or share this post with your network.

  Senior Biostatistician

  C4X Discovery Ltd, London Area, United Kingdom

  13 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  1mo
  • Report this post

  Last week, C4X's Martin Connolly and Flora Shimi were at #ACR24 in #WashingtonDC. Encouraged by the progress in personalised medicine!    The meeting highlighted how crucial data is in understanding the biology driving an individual's rheumatic disease - fascinating to see new approaches being developed to match the right treatment to each patient's unique profile. A key challenge remains: diagnosing and treating early enough with the right therapy to optimize chances of durable remission. Very impressed by the posters and abstracts exploring NETosis and citrullination's role in RA pathogenesis. Giving us renewed confidence that our small molecule PAD4 inhibitor program is on the right path to making a real difference for patients. Next stop… Barcelona in June 2025 for #EULAR25!

  27 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  1mo
  • Report this post

  Look out for C4XD's Flora Shimi and Martin Connolly at ACR Convergence 2024 to learn more about the exciting developments in C4XD’s immuno-inflammation pipeline. https://lnkd.in/eNxSd_km #inflammation #drugdiscovery #biotech #ACR2024

  14 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  1mo
  • Report this post

  With London Life Sciences’ week hotting up for next week, let us know if you would like to join Bhavna Hunjan Nick Ray and Emma Thomas to learn more about the incredible work we do in immuno-inflammation. Jefferies ICR Healthcare (Europe) #inflammation #drugdiscovery BioIndustry Association (BIA) BioCentury Inc. #biotech

  33 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  1mo
  • Report this post

  We are delighted that C4XD’s genetics stratification platform, PatientSeek, has been included in the DBT Genomics Spotlight:  https://lnkd.in/gAWAWgAx   PatientSeek employs a unique mathematical approach to analyse datasets containing patients’ genetic records together with other information such as electronic health records. When combined and analysed by PatientSeek, the data can provide a statistically significant predictive ‘genetic response signature’ to, for example, identify likely responder and non-responder populations to a particular therapeutic. Genetic signatures, compared to clinical and omic biomarkers, have the significant advantage of not changing over time and are independent of disease progression. The identification of likely ‘responders’ allows for a streamlined and hence faster Phase 3 recruitment and the promise of a greater efficacy readout. To learn more about PatientSeek, see https://lnkd.in/g_bFbdPW   #precisionmedicine #drugdiscovery #inflammation

  Emma Delgado

  MedTech Senior Sector Manager

  2mo

  It’s official – the Department for Business and Trade Genomics Spotlight has been launched with an appropriate 5th November bang! 🎇 🧬 I am very proud to have been the curator of this document which will be significant in creating export opportunities for UK genomics businesses and to showcase the latest developments that make the UK a hub for business, research and investment across wider NHS infrastructures and research institutes. While the Spotlight cannot be comprehensive of the depth of business in the UK, it showcases the breadth of UK capabilities, with an aim to promote UK plc and the healthcare institutions in place to markets around the world. 🚀 Dame Sue Hill will introduce this piece of work later today alongside Chief Scientific Advisors and Officers of the devolved nations, who have all contributed to the foreword. They will be at the British Society for Genetic Medicine Conference, when they speak on a pertinent panel on Developments in Genomics - a National Effort.   🌍 Our international launch is just days away as well when Mark Oakes and myself take UK genomics international at the MEDICA - Leading International Trade Fair! Meanwhile we’ll be reaching out to all our commercial officers in embassies around the world to ensure the best possible outreach for all this excellence.   👩⚕️ I hope that when you read the Spotlight, it is a reminder of the world leading genomics capabilities we have in the UK - from the NHS Genomic Medicine Service which is the first national healthcare system in the world to offer Whole Genome Sequencing (WGS) as part of routine care, to world leading institutions and research cohorts, to the ever-expanding innovation of UK small businesses – and shows how much the UK has to offer.   The Department for Business and Trade has worked closely with the NHS, including NHS England and all three of the devolved nations, other government departments and trade associations as well as encouraging input from several key organisations and companies in the UK. With a special shout out to PHG Foundation for their expert knowledge on the wider ecosystem. It is a great example of cross-sector collaboration to promote UK plc meaningfully. After a false start, a general election, and changes of policy, I am grateful to everyone who has persevered to make this a success. With a massive thank you to all those who contributed and made this happen, we couldn’t have done it without you! 👏 👏 👏   🗣️ If you have any questions about the Spotlight, are a UK business in the genomics space, or a potential investor into genomics in the UK, please feel free to reach out, I’d love to work with you on this exciting sector!

  10 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  2mo
  • Report this post

  Join C4XD’s VP of Translational Science, Simon Young, as he talks to Singular, Building Biotech Better, podcast: Careers in Discovery. Simon leads us through his often insightful and exciting career from his early days in the veterinary field to biotech & diagnostic research before bringing his expertise in precision medicine to C4XD. Hear more here https://lnkd.in/dbRZtnc6 #precisionmedicine #inflammation #drugdiscovery

  …more

  Simon Young, C4X Discovery | Careers in Discovery

  careers-in-discovery.podbean.com

  27 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  2mo
  • Report this post

  Brilliant to see this first disclosure of studies conducted within the collaboration between Garvan Institute of Medical Research and C4X Discovery Ltd which has demonstrated the link between patient sub-groups identified by C4XD's PatientSeek genetics platform and clinical data analysed by Prof Antony Cooper's group at Garvan. This supports the hypothesis that Parkinson's is a genetically heterogenous disease for which precision medicine will play a major part in addressing treatment needs, and also provides clinical validation of our Patientseek platform which we are currently applying to our own drug discovery programs as we prepare for the clinic.

  Garvan Institute of Medical Research

  23,115 followers

  3mo

  New research points to personalised Parkinson’s disease treatment. Imagine a future where Parkinson’s disease therapy isn’t one-size-fits-all, but tailored to each individual’s genetic makeup. Garvan’s A/Prof Antony Cooper presented new findings at the International MDS Congress in Philadelphia recently. Working with C4X Discovery, his team has identified genetic signatures linked to different treatment responses in Parkinson’s disease Phase 3 clinical trials. This research suggests that tailoring Parkinson’s treatment to a patient’s genetic subgroup could improve efficacy – an approach that may lead to more effective symptom management and potentially better outcomes. Congratulations to A/Prof Cooper and his team on a study that highlights the potential of precision medicine in Parkinson’s care. #ParkinsonsResearch #PrecisionMedicine #GarvanInstitute #Genetics

  19 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  2mo
  • Report this post

  Our CEO, Clive Dix.HonFBPhS, recently spoke to Ashley Yeo at Citeline In Vivo to discuss our recent success with our PatientSeek platform, which has identified genetic signatures that predict patient response to vedolizumab in inflammatory bowel disease (IBD), and outlines the potential for the PatientSeek platform in a range of chronic inflammatory diseases. To read the full article: https://lnkd.in/eANNdCKZ #C4XD #immunology #Biotech #Innovation

  23 Like Comment Share
• C4X Discovery Ltd

  4,907 followers

  3mo
  • Report this post

  We are excited to announce that our precision medicine genomics-based platform, “PatientSeek”, has identified a genetic response signature that distinguishes responder and non-responder groups amongst patients with ulcerative colitis, an IBD, following treatment with the a4b7 integrin antibody vedolizumab.  To learn more see https://lnkd.in/dWxnc7KF #IBD #inflammation #drugdiscovery #ulcerativecolitis

  51 2 Comments Like Comment Share

Join now to see what you are missing

• Find people you know at C4X Discovery Ltd
• Browse recommended jobs for you
• View all updates, news, and articles

Join now

Similar pages

• Bioptimus

  Biotechnology Research

  Paris, Île-de-France

• InVivo Biosystems

  Biotechnology Research

  Eugene, Oregon

• Metagenomi

  Biotechnology Research

  Emeryville, California

• Isomorphic Labs

  Biotechnology Research

• MediLink Therapeutics

  Biotechnology Research

  Suzhou, Jiangsu

• Owkin

  Biotechnology Research

  New York, NY

• Remix Therapeutics

  Biotechnology Research

  Watertown, MA, MA

• MOMA Therapeutics

  Biotechnology Research

  Cambridge , Massachusetts

• Insilico Medicine

  Biotechnology Research

  Boston, Massachusetts

• ReCode Therapeutics

  Biotechnology Research

Show more similar pages Show fewer similar pages

Funding

C4X Discovery Ltd 2 total rounds

Last Round

Post IPO equity Oct 6, 2016 External Crunchbase Link for last round of funding

US$ 6.7M

See more info on crunchbase More searches More searches

• • Graduate Software Engineer jobs
  • Product Manager jobs
  • Consultant jobs
  • Analyst jobs

Agree & Join LinkedIn

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Sign in to see who you already know at C4X Discovery Ltd

Sign in

Welcome back

Email or phone Password Show Forgot password? Sign in

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

New to LinkedIn? Join now

or

New to LinkedIn? Join now

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

LinkedIn

LinkedIn is better on the app

Don’t have the app? Get it in the Microsoft Store.

Open the app